TransCode Therapeutics (NASDAQ: RNAZ), a clinical-stage immuno-oncology company, has announced significant advancements in its global intellectual property portfolio. The company received acceptance from IP Australia for Patent Application No. 2019349817, which covers therapeutic nanoparticle compositions designed to deliver small interfering RNA (siRNA) molecules for cancer treatment. The allowed claims encompass nanoparticle compositions and methods of use across various cancers, including colon, lung, breast, pancreatic, and ovarian cancers. This patent is expected to proceed to grant with a projected expiration date of September 6, 2039.
In addition, TransCode received a Notice of Allowance from the Japan Patent Office, followed by the grant and issuance of Japanese Patent No. 7886877. This patent covers RNA-based immunomodulatory compositions designed to selectively activate innate immune pathways within tumors and the tumor microenvironment. The Japanese claims include compositions targeting cancers expressing miR-21 and nanoparticle-enabled delivery approaches incorporating magnetic or polymer-coated systems.
These developments are crucial for TransCode as they bolster the company's intellectual property protection for its innovative RNA-based cancer therapies. The patents provide broad coverage for key technologies that could potentially treat a wide range of high-risk and advanced cancers. For investors, this news signals progress in securing market exclusivity for TransCode's pipeline, which may enhance the company's value proposition and attract partnership opportunities. The full press release can be accessed at https://ibn.fm/Pqy4e.
TransCode Therapeutics is pioneering immuno-oncology and RNA therapeutic treatments. Its lead therapeutic candidate, TTX-MC138, targets metastatic tumors that overexpress microRNA-10b, a well-documented biomarker of metastasis. The company also has a portfolio of other first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells.
The global patent portfolio expansion underscores TransCode's commitment to protecting its proprietary technologies. The Australian patent, once granted, will provide protection until 2039, while the Japanese patent secures rights for RNA-based immunomodulatory compositions. These patents are expected to support the company's commercialization efforts and facilitate potential collaborations.
InvestorWire, a specialized communications platform, distributed the announcement. InvestorWire is part of the Dynamic Brand Portfolio at IBN, which offers extensive wire solutions, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and corporate communications solutions. For more information, visit InvestorWire. Full terms of use and disclaimers are available at https://www.InvestorWire.com/Disclaimer.
